pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
630
stories
Sep 14, 26
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 14, 26
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
Sep 11, 26
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
biopharma dive
Sep 11, 26
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
Sep 11, 26
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
Sep 11, 26
Novartis drags peers down with triple asset stumble
biospace
Sep 11, 26
Novartis drags peers down with triple asset failure
biospace
Sep 11, 26
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
Sep 10, 26
Why two promising heart drugs flopped and what’s next
stat
Sep 10, 26
11 companies hiring in California now
biospace
Sep 9, 26
Kura spins diabetes work into a Lilly-backed biotech startup
biopharma dive
Sep 9, 26
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
biopharma dive
Sep 9, 26
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
biospace
Sep 9, 26
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
biospace
Sep 9, 26
Kura Oncology spins out diabetes pipeline with $50M and Lilly's help
endpoints
Sep 9, 26
STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea
stat
Sep 9, 26
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
Sep 9, 26
Luma locks down 15-year, $410M fund for life science investments
fiercebiotech
Sep 9, 26
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
fiercebiotech
Sep 9, 26
Beyond China: Five other overseas destinations for biopharma dollars
biospace
Sep 9, 26
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
Sep 8, 26
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
Sep 8, 26
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
Sep 8, 26
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
Sep 8, 26
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
Sep 8, 26
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
Sep 8, 26
Moonwalk pulls in $70M to take fat-targeting RNAi obesity candidate to clinic
biospace
Sep 8, 26
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
biospace
Sep 8, 26
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
← prev
page 8 of 21
next →
